文献速递肾小球疾病遗传性与小管间质肾病

C3肾小球病与原发性免疫复合物膜增生性肾小球肾炎的现有及新兴治疗

Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis.
PubMed 文献 · Kidney Int Rep · 2025-11-05

C3肾小球病(C3G)和原发性免疫复合物膜增生性肾小球肾炎(IC-MPGN)是补体系统失调导致的罕见肾病,10年内高达50%患者进展至肾衰竭。传统治疗以支持和对症免疫抑制为主,近期靶向补体抑制剂(iptacopan和pegcetacoplan)的3期试验取得阳性结果。本文综述了补体抑制剂对蛋白尿、eGFR和肾脏病理等替代终点的效应及待解决问题。

要点

  • C3G和原发性IC-MPGN由补体失调驱动,传统治疗非特异性。
  • Iptacopan(因子B抑制剂)和pegcetacoplan(C3/C3b抑制剂)3期试验阳性。
  • 补体抑制剂对蛋白尿、eGFR和病理的效应及患者选择等仍待明确。

核心结论

  • 靶向补体抑制剂在C3G和原发性IC-MPGN的3期试验中取得阳性结果,为患者提供了新的治疗选择。

研究设计与样本

  • 本文为综述,总结了补体抑制剂在C3G/原发性IC-MPGN中的现有证据和待解决问题。

主要发现

  • Iptacopan在成人原生肾脏C3G的3期试验中取得阳性结果。
  • Pegcetacoplan在成人及青少年原生或移植后C3G或原发性IC-MPGN的3期试验中取得阳性结果。

关键数值与推荐

  • C3G和原发性IC-MPGN患者10年内高达50%进展至肾衰竭。
  • 补体抑制剂疗效的替代终点包括蛋白尿、eGFR和肾脏活检组织学。

临床怎么用

  • 补体抑制剂可用于C3G和原发性IC-MPGN患者,但需关注患者选择、治疗疗程和监测。

局限性

  • 补体抑制剂的最佳治疗持续时间、监测方法和候选患者人群尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

C3 glomerulopathy (C3G) and primary (idiopathic) immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney diseases characterized by dysregulation of the complement system and progressive deposition of C3 and its breakdown products in the glomeruli, ultimately leading to kidney failure in up to 50% of patients within 10 years. Until recently, standard approaches to treatment included supportive measures common to many kidney diseases and immunosuppression to mitigate inflammation, rather than specific therapies addressing the underlying C3 dysregulation. However, recent advances in targeted complement inhibitor therapy have been made in these diseases with positive results from phase 3 clinical trials of both the factor B inhibitor, iptacopan (in adults with native kidney C3G) and the C3/C3b inhibitor, pegcetacoplan (in adults and adolescents with native or posttransplant C3G or primary IC-MPGN). In this review, we summarize what is known and what questions still remain regarding the effect of complement inhibitors on widely accepted surrogate end points for efficacy in C3G/primary IC-MPGN (proteinuria, estimated glomerular filtration rate [eGFR], and kidney biopsy histology). Additional controversies, including candidate patient populations, optimal treatment duration, and how best to monitor patients on complement inhibitor therapy are also discussed, in an effort to prepare the nephrology community for innovative therapeutic options for patients whose long-term prognosis has generally been dismal.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kavanagh D, Ariceta G, Vivarelli M, et al. Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis. Kidney Int Rep. 2025. PMID: 41541782. doi:10.1016/j.ekir.2025.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。